

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION July 29, 2001 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2134.2006-001	APPLICATION NO.	1-971 U.S. Pat. 09/981586 10/17/01
APPLICANT Raymond J. Bergeron, Jr.		FILING DATE	GROUP 1626

U.S. PATENT DOCUMENTS

EXAM- INER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AA	3,809,754	05/07/74	Bertrand	424	270	
AB	3,882,110	05/06/75	Clemence, et al.	260	247.1	
AC	4,367,233	01/04/83	Clark, et al.	424	270	
AD	4,406,905	09/27/83	Zähner, et al.	424	263	
AE	4,457,936	07/03/84	Draeger, et al.	424	270	
AF	5,840,739	11/24/98	Bergeron, Jr.	514	365	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
AL 1292 170	11/10/72	United Kingdom	—	—	
AM 1320534	13/06/73	Great Britain	—	—	
AN 2245 560	21/03/74	Germany	—	—	
AO 2 247 243	09/05/75	France	—	—	
AP 30 02 989	30/07/81	Germany	—	—	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


AR	Abstract for Accession Number 80:146142 from Chemical Abstract Database, 1974.
AS	Abstract for Accession Number 83:206330 from Chemical Abstract Database, 1975.
AT	Bergeron, "Iron: A Controlling Nutrient in Proliferative Processes," Trends in Biochem. Sci., 11:133-136 (1986).


EXAMINER

DATE CONSIDERED

M

10/02

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2134.2006-001	APPLICATION NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		APPLICANT Raymond J. Bergeron, Jr.	
July 29, 2001		FILING DATE 10/19/2001	GROUP 1626
(Use several sheets if necessary)			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
AU	Bergeron, et al., "Synthesis and Biological Evaluation of Hydroxamate-Based Iron Chelators," <i>J. Med. Chem.</i> , 34:3182-3187 (1991).		
AV	Bergeron, et al., "A Comparison of the Iron-Clearing Properties of 1,2-Dimethyl-3-Hydroxypyrid-4-One 1,2-Diethyl-3-Hydroxypyrid-4-One and Deferoxamine," <i>Blood</i> , 79:1882-1890(1992).		
AW	Bergeron, et al., "The Desferrithiocin Pharmacophore," <i>J. Med. Chem.</i> , 34:1411-1417 (1994).		
AX	Bickel, et al., "Metabolic Properties of Actinomycetes. Ferrioxamine B," <i>Helv. Chim. Acta</i> , 43:2129-2138 (1960).		
AY	Brittenham, "Pyridoxal Isonicotinoyl Hydrazone: An Effective Iron-Chelator After Oral Administration," <i>Semin. Hematol.</i> , 27:112-116 (1990).		
AZ	Finch, et al., "Ferrokinetics in Man," <i>Medicine (Baltimore)</i> , 49:17-53 (1970).		
AR2	Finch, et al., "Perspectives in Iron Metabolism," <i>N. Engl. J. Med.</i> , 306:1520-1528 (1982).		
AS2	Finch, et al., "Iron Metabolism," <i>Clin. Physiol. Biochem.</i> , 4:5-10 (1986).		
AT2	Ganguly, P.K., and Gupta, B.M., "Antiviral Activity of Isoquinolines Carbazoles and Other Miscellaneous Synthetic Chemicals in Mice," <i>Indian J. Med. Res.</i> , 63(10):1418-1425 (1975).		
AU2	Grady, et al., "Rhodotorulic Acid-Investigation of its Potential as an Iron-Chelating Drug," <i>J. Pharmacol. Exp. Ther.</i> , 209:342-348 (1979).		
AV2	Grady, et al., "HBED: A Potential Oral Iron Chelator," <i>Ann. N.Y. Acad. Sci.</i> , 612:361-368 (1990).		
AW2	Guterman, et al., "Feasibility of Enterochelin as an Iron-Chelating Drug: Studies with Human Serum and a Mouse Model System," <i>Gen. Pharmac.</i> , 9:123-127 (1978).		
AX2	Hallberg, "Bioavailability of Dietary Iron in Man," <i>Ann. Rev. Nutri.</i> , 1:123-147 (1981).		
AY2	Hoffbrand, "Transfusion Siderosis and Chelation Therapy," <i>Iron in Biochemistry and Medicine</i> , Volume II, page 449, (London, 1980).		
AZ2	Kishore, V., et al., "Synthesis of α -Poly-[N ⁺ -(2-aryl- Δ^2 -thiazoline-4-carbonyl)-L-lysines] with Antiviral Activity," <i>Indian Journal of Chemistry</i> , 15B:255-257(1977).		
AR3	Kontoghiorghes, et al., "1,2-Dimethyl-3-hydroxypyrid-4-one, an Orally Active Chelator for the Treatment of Iron Overload," <i>Lancet</i> , 1:1294-1295 (1987).		
EXAMINER		DATE CONSIDERED	
		10/07	

PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION January 09, 2002 (Use several sheets if necessary)		ATTORNEY DOCKET NO. 2134.2006-001		APPLICATION NO. 09/881,586		<div style="text-align: center;">  </div>	
APPLICANT Raymond J. Bergeron, Jr.		FILING DATE October 17, 2001		GROUP 1626			
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
AQ	WO94/11367	26-May-94	PCT				
AL2	WO97/36885	9-Oct-97	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
AZ3	Bergeron, R.J., et al. "Evaluation of Desferrithiocin and its Synthetic Analogues as Orally Effective Iron Chelators", <i>Journal of Medicinal Chemistry</i> , (1991), 34(7), 2072-2078						
AR4	Bergeron, R.J., et al. "Effects of C-4 Stereochemistry and C-4 Hydroxylation on the Iron Clearing Efficiency and Toxicity of Desferrithiocin Analogues", <i>Journal of Medicinal Chemistry</i> , (1999), 42(13), 2432-2440						
AS4	Jalal, M.A.F., et al. "Structure of Anguibactin, a Unique Plasmid-Related Bacterial Siderophore from the Fish Pathogen <i>Vibrio Anguillarum</i> ", <i>Journal of American Chemical Society</i> , (1989), 111(1), 292-296						
EXAMINER				DATE CONSIDERED			

RECEIVED

FEB 04 2002

TECH CENTER 1600/290C

10/02

<p>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION</p> <p>JUN 09 2003</p> <p>JUNE 5, 2003</p> <p>(Use several sheets if necessary)</p>	ATTORNEY DOCKET NO. 2134.2006-001	APPLICATION NO. 09/987586
	APPLICANT Raymond J. Bergeron, Jr.	
	FILING DATE October 17, 2001	CONFIRMATION NO. GROUP 7212/1001526

U.S. PATENT DOCUMENTS				
EXAM- INER NO. TIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
	AG	2002/0049316 A1	04/25/02	Halbert, <i>et al.</i>
	AH	3,274,207	09/20/66	Kollonitsch, <i>et al.</i>
	AI	4,457,935	07/03/84	Iwao, <i>et al.</i>
	AJ	4,558,059	12/10/85	Kawasaki, <i>et al.</i>
	AK	4,736,060	04/05/88	Tomuro, <i>et al.</i>
	AA2	4,775,675	10/04/88	Györgydeák, <i>et al.</i>
	AB2	4,902,700	02/20/90	Hayasi, <i>et al.</i>
	AC2	4,914,208	04/03/90	Jakob, <i>et al.</i>
	AD2	5,084,083	01/28/92	Lewis, <i>et al.</i>
	AE2	5,106,992	04/21/92	Magnin, <i>et al.</i>
	AF2	5,169,858	12/08/92	Rubin
	AG2	5,182,402	01/26/93	Lewis, <i>et al.</i>
	AH2	5,192,781	03/09/93	Bru-Magniez, <i>et al.</i>
	AJ2	5,385,922	01/31/95	Bron, <i>et al.</i>
	AK2	5,393,777	02/28/95	Crosa
	AK2	5,442,073	08/15/95	Eicken, <i>et al.</i>
	AA3	5,614,520	03/25/97	Kondo, <i>et al.</i>
	AB3	6,080,764	06/27/00	Chihiro, <i>et al.</i>
	AC3	6,372,912	04/16/02	Döring, <i>et al.</i>
	AD3	6,437,143	08/20/02	Moinet, <i>et al.</i>
	AE3	5,840,739	11/24/98	Bergeron, Jr.
	AF3	6,083,966	07/04/00	Bergeron, Jr.
	AG3	6,147,070	11/14/00	Facchini
	AH3	6,159,983	12/12/00	Bergeron, Jr.


EXAMINER

DATE CONSIDERED

<p>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION</p> <p>JUNE 5, 2003</p> <p>(Use several sheets if necessary)</p>	<p>ATTORNEY DOCKET NO. 2134.2006-001</p>	<p>APPLICATION 09/981,586</p>
	<p>APPLICANT Raymond J. Bergeron, Jr.</p>	
	<p>FILING DATE October 17, 2001</p>	<p>CONFIRMATION NO. 7212</p>

FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
	AM2	EP 0214101 A2	11 MAR 87	Europe	
	AN2	EP 0214933 A2	18 MAR 87	Europe	
	AO2	EP 0513379 B1	11 SEP 96	Europe	
	AP2	WO 99/53039	21 OCT 99	PCT	
	AQ2	WO 01/27119 A2	19 APR 01	PCT	
	AL3	WO 00/16763	30 MAR 00	PCT	
	AM3	1382887	02 MAY 75	United Kingdom	

Re Blue










SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION JUN 09 2003 JUNE 5, 2003 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2134.2006-001	APPLICATION NO. 09/981,588
	APPLICANT Raymond J. Bergeron, Jr.	
	FILING DATE October 17, 2001	CONFIRMATION NO. GROUP 7212 1626

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AT4	Fritsch, G., <i>et al.</i> , "Plasmodium falciparum: Inhibition in vitro with Lactoferrin, Desferrithiocin, and Desferrirocinn," <i>Experimental Parasitology</i> 63:1-9 (1987).	
AU4	Henry, D.W., "Chemotherapeutic Nitroheterocycles. Derivatives of 5-Nitrothiazole-2-carboxaldehyde and 5-Nitrothiazole-2-carboxylic Acid," <i>J. Med. Chem.</i> 12(2):303-306 (1969).	
AV4	Stahel, E., <i>et al.</i> , "Iron Chelators: In vitro Inhibitory Effect on the Liver Stage of Rodent and Human Malaria," <i>Am. J. Trop. Med.-Hyg.</i> 39(3):236-240 (1988).	
AW4	Ullmanns Encyclopedia of Industrial Chemistry, 5 th Edition Vol. 14A, "ion exchangers," pp. 446-456, YEAR NOT AVAILABLE	
AX4	Bergeron, R.J., <i>et al.</i> , "A Comparative Study of the Iron-Clearing Properties of Desferrithiocin Analogues With Desferrioxamine B in a <i>Cebus</i> Monkey Model," <i>Blood</i> , 81(8):2166-2173, (1993).	
AY4	Bergeron, R.J., <i>et al.</i> , "An Investigation of Desferrithiocin Metabolism," <i>J. Med. Chem.</i> , 37(18):2889-2895, (1994).	
AZ4	Bergeron, R.J., <i>et al.</i> , "Desazadesmethyldesferrithiocin Analogues as Orally Effective Iron Chelators," <i>J. Med. Chem.</i> , 42(1):95-108, (1999).	
AR5	Bergeron, R.J., <i>et al.</i> , "Evaluation of the Desferrithiocin Pharmacophore as a Vector for Hydroxamates," <i>J. Med. Chem.</i> , 42(15):2881-2886, (1999).	
AS5	Bergeron, R.J., <i>et al.</i> , "Evaluation of Desferrithiocin and Its Synthetic Analogues as Orally Effective Iron Chelators," <i>J. Med. Chem.</i> , 34(7):2072-2078, (1991).	
AT5	Bergeron, R.J., <i>et al.</i> , "Pharmacokinetics of Orally Administered Desferrithiocin Analogs in <i>Cebus Apella</i> Primates," <i>Drug Metabolism and Disposition</i> , 27(12):1496-1498, (1999).	
AU5	Bergeron, R.J., <i>et al.</i> , "Synthesis and Biological Evaluation of Naphthyl-desferrithiocin Iron Chelators," <i>J. Med. Chem.</i> , 39(8):1575-1581, (1996).	
AV5	Bergeron, R.J., <i>et al.</i> , "The Origin of the Differences in (R)- and (S)-Desmethyldesferrithiocin: Iron-Clearing Properties," <i>Annals of the NY Academy of Sciences</i> , 850:202-216, (1998).	

EXAMINER <i>Ram J. Bergeron</i>	DATE CONSIDERED 1/6/05
------------------------------------	---------------------------

<p>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION</p> <p>JUN 09 2003</p> <p>JUNE 5, 2003</p> <p>(Use several sheets if necessary)</p>	ATTORNEY DOCKET NO. 2134.2006-001	APPLICATION NO. 09/981,586
	APPLICANT Raymond J. Bergeron, Jr.	
	FILING DATE October 17, 2001	CONFIRMATION NO. 7212

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AW5	Bierer, B.E. and Nathan D.G., "The Effect of Desferrithiocin, an Oral Iron Chelator, on T-Cell Function," <i>Blood</i> , 76(10):2052-2059, (1990).
	AX5	Cragg, L., et al., "The Iron Chelator L1 Potentiates Oxidative DNA Damage in Iron-Loaded Liver Cells," <i>Blood</i> , 92(2):632-638, (1998).
	AY5	Dean, R.T. and Nicholson, P., "The Action of Nine Chelators on Iron-Dependent Radical Damage," <i>Free Rad. Res.</i> , 20(2):83-101, (1994).
	AZ5	Re, R., et al., "Antioxidant Activity Applying an Improved ABTS Radical Cation Decolorization Assay," <i>Free Rad. Biol. Med.</i> , 26(9/10):1231-1237, (1999).
	AR6	Abstract No. NDN-050-0012-6956-2 obtained from Nerac for EP 0214101 A2; Publication date 11 MAR 87.
	AS6	Abstract No. NDN-050-0012-7442-9 obtained from Nerac for EP 0214933 A2; Publication date 18 MAR 87.

EXAMINER 	DATE CONSIDERED 1/6/05
---	---------------------------